Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt;–EGFR Inhibition in Colorectal Cancer

Rona Yaeger; Riccardo Mezzadra; Jenna Sinopoli; Yu Bian; Michelangelo Marasco; Esther Kaplun; Yijun Gao; HuiYong Zhao; Arnaud Da Cruz Paula; Yingjie Zhu; Almudena Chaves Perez; Kalyani Chadalavada; Edison Tse; Sudhir Chowdhry; Sydney Bowker; Qing Chang; Besnik Qeriqi; Britta Weigelt; Gouri J. Nanjangud; Michael F. Berger; Hirak Der‐Torossian; Kenna Anderes; Nicholas D. Socci; Jinru Shia; Gregory J. Riely; Yonina R. Murciano‐Goroff; Bob T. Li; James G. Christensen; Jorge S. Reis‐Filho; David B. Solit; Elisa de Stanchina; Scott W. Lowe; Neal Rosen; Sandra Misale

doi:10.1158/2159-8290.30849241

Abstract

C106 resistant cells drug withdrawal and Patient #12 MSK-Impact data

Related Publications

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Ramin Nazarian , Hubing Shi , Qi Wang +13 more

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel clas...

2010 Nature 2132 citations

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

James Bean , Gregory J. Riely , Marissa N. Balak +4 more

Abstract Purpose: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are associated with sensitivity of lung adenocarcinomas to ...

2008 Clinical Cancer Research 276 citations

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

Lili Liu , Sanford D. Markowitz , Stanton L. Gerson

Cells with the mutator phenotype are tolerant to methylating damage from N-methylnitrosourea and N-methyl-N'-nitro-N-nitrosoguanine, exhibit replication repair errors, and have ...

1996 PubMed 237 citations

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi , Francisco Sánchez-Vega , Konnor La +29 more

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of pati...

2018 Journal of Clinical Oncology 1371 citations

Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization

Paraskevi Giannakakou , Dan L. Sackett , Yoon‐Koo Kang +4 more

Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations involving tubulin. We report two paclitaxel-resistant sublines derived from 1A9 human ovari...

1997 Journal of Biological Chemistry 679 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

Download PDF (Free) View on DOI.org

Social Impact

Altmetric

Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

CrossRef

Cite This

APA Style

                            
                                    Rona Yaeger, 
                                
                                    Riccardo Mezzadra, 
                                
                                    Jenna Sinopoli
                                
                                et al.
                            
                            (2025). 
                            Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS&lt;sup&gt;G12C&lt;/sup&gt;–EGFR Inhibition in Colorectal Cancer. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30849241

Identifiers

DOI: 10.1158/2159-8290.30849241

Data Quality

Data completeness: 70%

Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer